Physician profile
Angelo Costas
NPI 1104874791
$2,947.26
in general payments reported to CMS, 2019-2025
30 companies · $224 in 2025
The $224 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,350 · 2020: $386 · 2021: $114 · 2022: $253 · 2023: $233 · 2024: $388 · 2025: $224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $845.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $844.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $580.03 | 2019-2024 | |
| Novo Nordisk INC | $385.19 | 2019-2025 | Wegovy |
| Pfizer INC. | $296.75 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $228.87 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Glaxosmithkline, LLC. | $168.84 | 2019-2024 | Arexvy, Shingrix |
| Amgen INC. | $148.19 | 2019-2023 | Prolia, Evenity |
| Astrazeneca Pharmaceuticals Lp | $137.40 | 2019-2020 | |
| Exact Sciences Corporation | $117.33 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $101.45 | 2019-2023 | Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.40 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $91.46 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $91.31 | 2019-2020 | |
| Lilly USA, LLC | $72.43 | 2019-2025 | Zepbound |
| Gilead Sciences, INC. | $56.55 | 2019-2022 | |
| Alk-Abello, INC | $38.75 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $33.02 | 2019 | |
| Seqirus USA INC | $31.77 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.27 | 2019 | |
| Vivus LLC | $29.91 | 2019 | |
| Abbott Laboratories | $27.77 | 2020 | |
| Csl Behring | $25.63 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.42 | 2019 | |
| Astellas Pharma US INC | $21.31 | 2020 | |
| Ironwood Pharmaceuticals, INC | $20.00 | 2020 | |
| Medtronic USA, INC. | $17.67 | 2019 | |
| Shire North American Group INC | $17.44 | 2019 | |
| Kaleo, INC. | $16.30 | 2019 | |
| Abbvie INC. | $14.56 | 2019 | |
| Arbor Pharmaceuticals, INC. | $13.25 | 2019 | |
| Avion Pharmaceuticals | $11.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angelo Costas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.